Dapagliflozin in Chronic Kidney Disease Management

Primary Benefits in CKD

The American Diabetes Association recommends dapagliflozin to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression, with a 39% reduction in the primary composite outcome compared to placebo (HR 0.61 [95% CI 0.51–0.72]; P < 0.001) 1, 2
Dapagliflozin reduces the kidney-specific composite outcome by 44% (HR 0.56 [95% CI 0.45–0.68]; P < 0.001) in patients with chronic kidney disease 3, 4

Dapagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure by 29% (HR 0.71 [95% CI 0.55–0.92]; P = 0.009) in patients with chronic kidney disease 1, 2
All-cause mortality is significantly decreased in patients taking dapagliflozin compared to placebo (P < 0.004) in the context of chronic kidney disease 3, 4

Dapagliflozin can be used in patients with eGFR as low as 20 mL/min/1.73 m², with a recommended dose of 10 mg orally once daily 5
The DAPA-CKD trial included patients with eGFR 25-75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio (UACR) 200-5,000 mg/g, demonstrating efficacy in this population 1, 2

Common side effects of dapagliflozin include increased urination and genitourinary infections, as reported in the Circulation journal 6

Dapagliflozin provides significant mortality and morbidity benefits in CKD patients, regardless of diabetes status, and should be considered for treatment 5